On the 30-share Sensex platform, ICICI Bank, Sun Pharma, Axis Bank, Bajaj Finserv, Kotak Bank, Infosys emerged early losers ...

KR Choksey recommended accumulate rating on Sun Pharmaceutical Industries with a target price of Rs 1967 in its research report dated October 30, 2024.

IST, the barometer index, the S&P BSE Sensex, was down 116.24 points or 0.15% to 80,258.88. The Nifty 50 index lost 23.50 points or 0.10% to 24,443.35.

Discover the Sun Pharma Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Mumbai: Sun Pharmaceutical Industries Limited has presented data strengthening the clinical rationale for the use of WINLEVI (clascoterone) cream 1% to treat acne. In poster presentations at ...

Sun Pharmaceutical Industries declared its Q2 results on October 28, 2024, showcasing a robust financial performance. The ...

The application was filed in a petition by Daiichi Sankyo seeking execution of a ₹ 3,500-crore Singapore tribunal arbitral award passed in its favour and against brothers Malvinder Mohan Singh and ...

Watch the interview of CS Muralidharan, CFO of Sun Pharma, on ET Now. Sun Pharma's Q2 results were impressive, with higher PAT and margins surpassing expectations. The company also reduced its R&D ...

Most brokerages retained ratings and target prices for Sun Pharmaceutical Industries after its second quarter earnings beat ...

Sun Pharmaceuticals' shares fell by 2% despite a strong financial performance in the second quarter. The company reported a ...

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s ...